Search the Newsreel

Should Value Investors Buy Boise Cascade (BCC) Stock?

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong …

Why TerrAscend Corp. stock surged yesterday

Why ASOS (LSE:ASC) And Boohoo (LSE:BOO) Remain On The UK Penny Stock Radar

Ascentage Pharma (NASDAQ: AAPG) CEO ranks No.3 on Medicine Maker 2026 list

Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, has been recognized on The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The list honors 60 global leaders driving innovation in drug discovery and development. Dr. Yang's inclusion highlights his …

Masco Earnings Rise as Pricing and Tariff Refunds Lift 2026 Margins

Masco Corporation reported mixed results for Q2 2026, with earnings and margins sharply improved due to pricing, cost savings, and a significant tariff refund, but sales declined. The company's adjusted earnings per share rose 26% year-over-year, beating estimates, while net sales fell 2.9% and …

Precision Trading with Lemaitre Vascular Inc. (LMAT) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Lemaitre Vascular Inc. (LMAT) focusing on precision trading strategies and risk zones. It highlights near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with specific entry, target, and stop-loss levels for different …

Sei Investments Co. Boosts Stock Holdings in LeMaitre Vascular, Inc. $LMAT

Sei Investments Co. increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 30.7% in the first quarter, now holding 136,674 shares valued at $14.92 million. Other

Price to book forward of Erasca, Inc. – NASDAQ:ERAS

This article provides the "Price to book forward" financial metric for Erasca, Inc. (NASDAQ: ERAS). It appears to be a stub or data-focused entry from a financial platform, showing the company's ticker, exchange, and the specific financial value along with its change over a …

Metgasco Secures $5M SA Government Grants for Odin and Vali Appraisal Wells as Quarterly Revenue Falls to $292,450

Scotiabank Weighs in on Cascades' FY2026 Earnings (TSE:CAS)

Ascendis Pharma A/S (ASND) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Ascendis Pharma A/S (ASND), highlighting its current valuation score of 7.87 within the Biotechnology & Medical Research industry. It notes the P/E ratio is 36.18, which is below its recent high but significantly above its recent low. …

MAS Maintained by UBS -- Price Target Lowered to $94.00

UBS has maintained a "Buy" rating on Masco (MAS) but lowered its price target from $97.00 to $94.00, reflecting a cautious outlook despite strong company performance. According to GuruFocus, Masco is currently undervalued by 1.5% and boasts a GF Score™ of 88/100, indicating robust …

AUGUST 10, 2026 INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for purchasers of its common stock between January 14, 2025, and April 26, 2026. Investors who suffered substantial losses are encouraged to seek appointment as lead plaintiff …

Masco (MAS) Appoints Its First Chief Marketing Officer To Push Brand Growth

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Masco (NYSE:MAS) has appointed Brad Hiranaga as its first Chief Marketing Officer. The new role focuses on brand growth, digital acceleration, and customer-centric product and …

Boise Cascade Dividend Rises to 23 Cents, Paid Sept. 16

Boise Cascade Company (NYSE: BCC) announced a 5% increase in its quarterly dividend, raising it by $0.01 to $0.23 per share. This dividend will be paid on September 16, 2026, to stockholders of record as of September 1, 2026. Future dividend declarations are subject …

Press Release: Boise Cascade Company Announces 5% Quarterly Dividend Increase

Boise Cascade Company (BCC) announced a 5% increase in its quarterly dividend to $0.15 per share, payable on September 15, 2026, to shareholders of record as of August 30, 2026. This increase reflects the company's strong financial performance and commitment to returning value to …

Boise Cascade raises quarterly dividend to $0.23, payable Sept. 16

Boise Cascade (BCC) has announced a 5% increase in its quarterly cash dividend, raising it to $0.23 per share. This dividend is payable on September 16, 2026, to shareholders of record as of September 1, 2026. Future dividends will be subject to various financial …

MAS Q2 Deep Dive: Revenue Misses Estimates but Profitability Benefits from Tariff Refunds

MAS Q2 Deep Dive: Revenue Misses Estimates but Profitability Benefits from Tariff Refunds Home-building design and manufacturing company Masco Corporation (NYSE:MAS) fell short of the market's revenue expectations in Q2 CY2026, with sales falling 2.9% year on year to $1.99 billion. Its non-GAAP profit …

Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR

This page provides financial information for Ascendis Pharma A/S ADR (A1SN34) traded on BMFBOVESPA. It focuses on the "Price to book forward" metric and lists the company's trading status as "Market closed" with "No trades." The content is primarily a financial data page from …

LeMaitre Vascular Inc (LMAT) Institutional Confidence

LeMaitre Vascular Inc (LMAT) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This score reflects a quarter-over-quarter increase of 8.41% in institutional shareholding proportion, which currently stands at 102.98%. ETHSX is the largest institutional shareholder, …

Levi & Korsinsky Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS

Levi & Korsinsky, LLP is reminding investors of Erasca, Inc. (NASDAQ: ERAS) about a pending class action lawsuit with a lead plaintiff deadline of August 10, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, particularly concerning its comparisons to …

Shareholders of Erasca, Inc. (ERAS): Protect Your Rights Before August 10, 2026 - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Erasca, Inc. (NASDAQ:ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made false statements and concealed that ERAS-0015's preclinical data …

Ardmore Shipping (ASC) Stock Extends Rally As Tanker Margins Surge

Ardmore Shipping (ASC) reported strong Q2 2026 earnings, with basic EPS of US$1.48 and revenue of US$116.2m, driven by firm product and chemical tanker markets. The company's profitability and high profit margins caught investors' attention, despite concerns about potential rate normalization and increased future …

Boise Cascade, L.L.C. (BCC) Stock Forecasts

Argus has raised its target price for Boise Cascade, L.L.C. (BCC) to $84.00. The company, a producer of engineered wood products and plywood, is currently trading at $77.68. This report provides a quantitative analysis, suggesting a positive outlook for the stock.

Evercore ISI cuts Masco stock rating on strategic investment concerns By Investing.com

Evercore ISI downgraded Masco (NYSE:MAS) from Outperform to In Line, lowering its price target to $78 from $86 due to concerns over strategic investments and reduced earnings estimates. The analyst cited a lack of clarity around these investments, contributing to an 11% stock drop. …

ASC|Ardmore Shipping Corp|Price:16.745|Chg%:+0.355

TradingKey provides a comprehensive stock analysis of Ardmore Shipping Corp (ASC), assigning it a high score of 7.37/10, ranking it 4th in its industry. The report highlights the company's healthy fundamentals, high growth potential, and fair valuation, with analysts rating it as a "Buy." …

Ardmore Shipping: Q2 Earnings Snapshot

This article provides a snapshot of Ardmore Shipping's Q2 earnings. No specific financial details are available in the provided content, as it appears to be a placeholder or incomplete article.

Is Masco (MAS) Undervalued As Higher EPS Guidance Offsets A Revenue Miss?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Masco (MAS) drew fresh investor focus after second quarter results showed operating profit and earnings per share ahead of analyst expectations, even as revenue came in below …

Ardmore Shipping (ASC) Earnings Date and Reports 2026 $ASC

Ascendis Pharma A/S (ASND) Expected to Release Quarterly Earnings on Thursday

Ascendis Pharma A/S $ASND Stock Holdings Reduced by Tri Locum Partners LP

Empowered Funds LLC Acquires 14,438 Shares of Ascendis Pharma A/S $ASND

Masco (MAS) Stock Holds Firm as Tariff Fueled Margins Face Durability Questions

ERAS|Erasca Inc|Price:17.720|Chg%:-0.440

This article provides a detailed overview of Erasca Inc (ERAS) stock, including its current price of $17.72, a 2.42% daily decrease, and a market capitalization of $5.04 billion. It highlights significant year-to-date and 1-year price increases, analyst ratings showing a "Buy" consensus with a …

LeMaitre Vascular Inc (LMAT) Financial Health: Profitability & Balance Sheet Analysis

LeMaitre Vascular Inc (LMAT) has a robust financial status with a current financial score of 9.04, ranking 11th in the Healthcare Equipment & Supplies industry. The company demonstrated high operating efficiency with a 11.16% year-over-year increase in quarterly revenue to $66.55M and a 42.39% …

Ascendis Pharma A/S (ASND) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Ascendis Pharma A/S (ASND), focusing on its price momentum, support and resistance levels, and various technical indicators. The stock's current price momentum score is 3.21, ranking it low in the Biotechnology & Medical Research industry, and it …